ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ: INHX - News) announced today that a poster presentation describing preclinical data on INX-189, the lead compound from its HCV nucleotide polymerase inhibitor program, will be presented by Dr. Joseph M. Patti, Chief Scientific Officer and Senior Vice President of R&D, at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. The full abstract can be viewed at the AASLD website at www.aasld.org.

The poster (#1611 Patti, et al), entitled “Pharmacological Properties and In Vitro Characterization of INX-189, a Liver Targeted Phosphoramidate Nucleoside Analogue Inhibitor of NS5b” will be presented in the HCV Therapy: Preclinical and Early Clinical Development session from 8:00 am – 1:00 pm on Tuesday, November 3rd, 2009.